The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IF: 1/10 - 1/50. Acetone fixation of the antigen source is recommended prior to staining.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase.
Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed.
The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.
References for Anti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody (FITC) (ab32914)
This product has been referenced in:
Deng Q et al. Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology50:1380-91 (2009).
Read more (PubMed: 19821533) »
Deng Q et al. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol81:4244-54 (2007).
Read more (PubMed: 17192308) »